BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32656719)

  • 1. It Is Time to Rethink Biomarkers for Surveillance of Small Bowel Neuroendocrine Tumors.
    Tran CG; Sherman SK; Scott AT; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2021 Feb; 28(2):732-741. PubMed ID: 32656719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
    Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel.
    Woltering EA; Voros BA; Thiagarajan R; Beyer DT; Ramirez RA; Wang YZ; Mamikunian G; Boudreaux JP
    Pancreas; 2018 Aug; 47(7):843-848. PubMed ID: 29939909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Pancreastatin Predicts the Outcome of Surgical Cytoreduction in Neuroendocrine Tumors of the Small Bowel.
    Woltering EA; Voros BA; Beyer DT; Thiagarajan R; Ramirez RA; Mamikunian G; Boudreaux JP
    Pancreas; 2019 Mar; 48(3):356-362. PubMed ID: 30768573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.
    Andreasi V; Partelli S; Manzoni MF; Muffatti F; Di Filippo L; Crippa S; Corti A; Falconi M
    J Endocrinol Invest; 2022 Jun; 45(6):1209-1217. PubMed ID: 35122631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine differentiation in colorectal carcinomas.
    Syversen U; Halvorsen T; Mårvik R; Waldum HL
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level.
    Concors SJ; Sinnamon AJ; Ecker BL; Metz DC; Vollmer CM; Fraker DL; Roses RE
    HPB (Oxford); 2020 Jan; 22(1):83-90. PubMed ID: 31239188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
    Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
    Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
    Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
    QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
    Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
    AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASO Author Reflections: Indolent Growth and Small Bowel Neuroendocrine Tumor Management.
    Sherman SK; Tran CG; Howe JR
    Ann Surg Oncol; 2021 May; 28(5):2752-2753. PubMed ID: 33566244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.